| abstract |
The invention belongs to the technical field of biopharmaceuticals, and more specifically, relates to a long-acting HM-3 fusion protein molecule and its application. The present invention is based on the molecular sequence of HM-3. The active polypeptide HM-3 and its derivatives are connected to human Fc (IgG) fragments or Fc (IgG) mutant fragments through linker peptides (Linker) or directly to form a new The molecular entity. Its general formula is (HM-3) n -Linker-Fc(IgG), Fc(IgG)-Linker-(HM-3) n , or (HM-3) n -Linker-Fc(IgG)-Linker-( HM-3) n . The invention effectively prolongs the half-life of HM-3, has low cost, and overcomes the key problem of oligopeptide druggability. It can be used as a medicine with great potential for treating autoimmune diseases, neovascular diseases and osteoarthritis. |